Integrated Drug Discovery CRO Services for Pharmaceutical R&D
ChemDiv is a recognized global leader in drug discovery solutions. We offer fully integrated R&D Services to support pharmaceutical R&D projects.
Over the past 29 years ChemDiv has delivered hundreds of leads, drug candidates and new drugs in the area of CNS, Oncology, virology, inflammation, cardiometabolic and immunology, to pharma, biotech and academic partners around the globe.
Benefit from ChemDiv’s flexible CRO as a one-stop and cost-effective solution.
Focused and targeted libraries
114 predesigned screening libraries. Introduced by therapeutical areas, targets and mechanism of action.
Active Reference Sets
17 annotated libraries. Over 220,000 compounds with available bioactivity data, >25,000 targets, >1,000,000 activity data points across various areas.
Diversity libraries
Representative diversity sets cover space of billions compounds. 2D and 3D.
Building blocks
Search and purchase
Substructure Search for Screening Compounds
Search and purchase in the largest commercially available space. Regular new arrivals.
Download full database
Popular
Representative Diversity Libraries
50,000 / 100,000 / 150,000 compounds
Targeted Diversity Library
39,646 compounds
3D-Pharmacophore Based Diversity Library
52,000 compounds
Cardiovascular Library
22,203 compounds
Antiviral Library
65,937 compounds
miRNA targeted small molecule library
20,000 compounds
CNS MPO Library
28,284 compounds
CNS BBB Library
22,790 compounds
Happy Holidays 2023
The warmest congratulations on The New Year and Christmas from San Diego
PROTACs
DMSO
Dimethyl sulfoxide (DMSO) is an organic chemical polar compound in a liquid state under normal conditions. It is the aprotic solvent or the solvent which, when decomposed in solution, does not...
Science & Nature Reviews, February 2022. Part II
Neurophysiology
Kelava, I., Chiaradia, I., Pellegrini, L. et al. Androgens increase excitatory neurogenic potential in human brain organoids. Nature 602, 112–116 (2022)
Sex-based brain dif...
FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz
Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).
...
ChemDiv Company in publications and patents
We are passionate about the latest trends in life sciences and medicinal chemistry and closely monitoring the latest developments and discoveries in this area.
It means a lot to us if our custome...
Beyond binary: scaled molecular fingerprints for maximum diversity picking